Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche presents positive new RoActemra trial data

Roche presents positive new RoActemra trial data

10th November 2010

Roche has reported new clinical trial data which demonstrates the effectiveness of its rheumatoid arthritis (RA) drug RoActemra in both the long and short term.

In association with subsidiary Genentech, the company conducted a new phase III study in which the treatment was shown to prompt a rapid, measured response in patients as early as one week after administration commenced.

This was followed by an improvement in disease activity levels within four weeks of treatment, with the drug reaching its primary endpoint target of a 50 percent reduction in symptoms at 24 weeks.

The data comes in addition to findings from three other phase III studies, showing that RoActemra can deliver sustained improvements over nearly two years.

Dr Hal Barron, executive vice-president for product development and chief medical officer at Roche, said the results "provide further evidence of the long-term benefits of RoActemra in reducing the signs and symptoms in patients with moderate to severe RA".

Earlier this year, a combination of RoActemra and methotrexate was recommended by the National Institute for Health and Clinical Excellence for RA patients in the UK.ADNFCR-8000103-ID-800227193-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.